Sky Labs' CART BP pro at the Heart of New Research on Sleep Apnea and Nocturnal Hypertension
SEOUL, South Korea, April 28, 2025 /PRNewswire/ -- Sky Labs, a health-tech startup based in South Korea and the developer of CART BP pro—a ring-type, cuffless device for 24-hour blood pressure monitoring—announced that a research presentation by Professor Jin Oh Na introduced the application of CART BP pro in exploring the relationship between sleep and cardiovascular patterns, offering an opportunity to gain deeper insights into cardiovascular risks during sleep.
This study represents a meaningful step forward in cardiovascular research. Until now, studying the connection between sleep-disordered breathing and hypertension has been limited due to constraints in traditional measurement tools. With CART BP pro, researchers can gather uninterrupted blood pressure data, offering an opportunity to better understand cardiovascular patterns during sleep.
Professor Jin Oh Na of Korea University Guro Hospital's Cardiovascular Center presented a research plan under the theme " Sleep and Cardiovascular Health: Why It Matters" at the 2025 Annual Spring Scientific Conference of the Korean Society of Cardiology. His upcoming research will explore the correlation between sleep apnea and cardiovascular risks using CART BP pro to measure blood pressure noninvasively during sleep.
"Obstructive sleep apnea is a condition that affects cardiovascular health but is frequently underdiagnosed. In Korea, about 85% of OSA patients remain undiagnosed, often dismissed as simple snoring," said Professor Na. "We are planning a study to measure nighttime blood pressure every five minutes using CART BP pro, with the aim of developing a model that may help identify patients at risk and support long-term assessment."
CART BP pro offers several advantages for both clinical practice and research:
Professor Na pointed out that while polysomnography (PSG) is the current gold standard for diagnosing sleep apnea, it does not allow for precise blood pressure monitoring during sleep. He explained that cuff-based devices may disturb sleep due to pressure inflation and are not suitable for high-frequency nocturnal measurements. By using CART BP pro, researchers expect to collect more consistent, real-world data without interfering with sleep.
The 2025 Annual Spring Scientific Conference held from April 17 to 19 in Busan, Korea, was jointly hosted with the 29th Asian Pacific Society of Cardiology Congress and attended by leading cardiology experts from across the region.
Currently available at more than 1,300 hospitals and clinics throughout South Korea, CART BP pro has received regulatory approval from the Ministry of Food and Drug Safety (MFDS) and is eligible for national health insurance reimbursement, making it more accessible to a broader range of patients.
About Sky Labs
Founded in September 2015, Sky Labs is a leading healthcare startup that has developed CART (Cardio Tracker), a ring-shaped medical device designed for disease monitoring using heart signals collected through optical sensors. Following this, the company developed CART BP, a cuffless, ring-shaped device that enables 24-hour blood pressure monitoring, providing valuable treatment information and making a groundbreaking contribution to improving the quality of life for hypertension patients. Sky Labs has signed an exclusive domestic distribution agreement for CART BP pro with South Korea's Daewoong Pharmaceutical and is preparing for nationwide sales to hospitals, clinics, and general consumers.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
6 hours ago
- Korea Herald
Green Fertilizer Made with Air and Plasma: NitroCapt (Sweden) wins $2M Food Planet Prize 2025 for developing low-emission fertilizers
STOCKHOLM, June 13, 2025 /PRNewswire/ -- The Curt Bergfors Foundation is honored to announce that NitroCapt was awarded the Food Planet Prize, the world's biggest environmental award, on June 13 in Stockholm, Sweden. This recognition highlights their exceptional contributions and potential to disrupt the global nitrogen fertilizer industry. Nitrogen fertilizers are used for 50% of the world's food production and emit as much carbon dioxide as the aviation industry. Sweden-based NitroCapt has developed a novel, energy-efficient process that makes fertilizer through plasma-produced nitrate. NitroCapt's technology could improve access to green fertilizer across the world. In awarding the Prize to NitroCapt, the Food Planet Prize jury Co-Chair Johan Rockström commented: "Through NitroCapt's innovation, nitrogen fertilizer can now be produced by splitting nitrogen from the air with plasma technology simply needing green electricity as input. This technology reduces the use of energy tenfold, can be produced locally, avoids fossil-fuels entirely, while producing a nitrate fertilizer that can improve soil health and may be used sustainably by farmers across the world." Gustaf Forsberg, CEO and Founder of NitroCapt, added: "NitroCapt's mission is to decarbonize the nitrogen fertilizer industry. The current fossil-based process has reached its end point. We can also contribute to increased food production in areas that today have difficulties producing sufficient amounts. We are just about to finalize our industrial-scale pilot, and we have fertilizer in the field, but we're still not at the scale where we want to be. This Prize will be very important for us to bring our technology to the stage where we can start making a difference." About the Food Planet Prize The Curt Bergfors Food Planet Prize was established in Sweden in 2019, in acknowledgement of the perils that our current food systems pose to the health of people and the planet. The Prize supports initiatives that significantly reduce the environmental impact of the way we eat today. Unlike many awards, the Food Planet Prize recognizes initiatives for their potential future impact on the environment rather than past achievements. The Food Planet Prize's international jury consists of 10 leading specialists in complex Food Planet challenges. The jury is co-chaired by Johan Rockström and Magnus Nilsson.
Korea Herald
6 hours ago
- Korea Herald
Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels
CLEVELAND, June 13, 2025 /PRNewswire/ -- Primary Investigator, Bernardo Cortese MD, proudly announces the successful completion of patient enrollment in the TRANSFORM II randomized controlled trial (RCT). This pivotal study aims to evaluate the safety and efficacy of the MagicTouch Sirolimus-Coated Balloon (SCB) compared to an everolimus-eluting stent (EES) in treating de-novo coronary vessels. TRANSFORM II (Sirolimus-Coated Balloon Versus Drug-Eluting Stent in Native Coronary Vessels) is an investigator-driven trial sponsored by Fondazione Ricerca e Innovazione Cardiovascolare in Milano, Italy, and has now achieved its target enrollment of >1,820 patients. The final patient was enrolled on 6 th June 2025, marking a major milestone for the trial. Led by Study Chairman Prof. Bernardo Cortese (University Hospitals Harrington Heart & Vascular Institute, Cleveland, USA) and a distinguished steering committee, TRANSFORM II is one of the largest global randomized controlled trials evaluating drug-coated balloon and has enrolled patients from 52 centers across Europe, Asia and South America. Key features of the TRANSFORM II trial include: Prof. Bernardo Cortese, Study Chairman of TRANSFORM II, commented: "After 3 and a half years we were able to complete the enrollment in TRANSFORM II trial, a study that involved 52 centers across 3 continents, and this is amazing. The effort put by our Team in Fondazione RIC and each Investigator of the study led to a quite fast enrollment in such a big, ambitious study. Our goal is to advance the adoption of DCB in the coronary space, testing this sirolimus DCB with the most studied and used DES, in a daily patient population. Along with the guidance of the recently published DCB ARC guidelines, we are paving the route for the modern angioplasty era!". Coronary vessels of this size (which account for roughly 80% of patients undergoing percutaneous coronary interventions) present unique treatment challenges. Currently, interventional cardiologists must often choose a permanent implant namely a drug-eluting stent — effectively "caging" a small vessel — which may compromise long-term outcomes. The head-to-head comparison of MagicTouch SCB against a current standard of care (the EES family of drug-eluting stents) in TRANSFORM II is poised to provide critical evidence for an alternative approach. This trial has the potential to reshape treatment practices by establishing drug-coated balloons as the next viable option for patients with coronary artery disease. Drug-coated balloon technology has long been viewed as a promising solution for small, de-novo coronary lesions, and sirolimus is a viable alternative to the first generation of DCB eluting paclitaxel. Data from this large-scale RCT are expected to support a paradigm shift towards broader use of drug-coated balloons. Implanting a drug-eluting stent in a tiny artery is far from ideal for both patients and physicians, so a rigorous study validating the use of SCB was needed. TRANSFORM II is set to fulfill that need, with initial 12-month outcomes anticipated to shed light on the long-term benefits of avoiding permanent implants in coronary vessels. Dr. Manish Doshi, Founder & Managing Director of Concept Medical Group, commented: "The completion of patient enrollment in TRANSFORM II is a significant milestone in our mission to bring innovative drug-delivery technologies to the forefront of interventional cardiology. We are proud to scientifically support one of the largest global randomized trials evaluating sirolimus-coated balloon technology. This achievement reflects our commitment to clinical excellence, scientific rigor, and ultimately, better outcomes for patients around the world." About MagicTouch SCB The MagicTouch SCB, developed by Concept Medical Inc., utilizes proprietary Nanoluté technology to deliver sub-micron particles of sirolimus encapsulated in a biocompatible carrier, ensuring deep penetration into the vessel wall. The device has received CE Mark approval in Europe alongwith Breakthrough Device Designation & IDE Approval from the U.S. FDA for the treatment of small coronary vessels and in-stent restenosis with ongoing clinical trials. About Concept Medical Inc. Concept Medical Inc., headquartered in Tampa, Florida, has a global presence and is dedicated to enhancing patient care through cutting-edge research and development of drug-delivery technologies. Its proprietary platforms are designed to deliver pharmaceutical agents across vascular luminal surfaces with unparalleled precision. Concept Medical is the developer of the MagicTouch family of Sirolimus-Coated Balloons (SCB) – the world's first and most utilized SCB technology – well recognized for its versatility and efficacy in treating coronary and peripheral artery disease. The revolutionary MagicTouch and Abluminus product lines have been used to treat over a million patients globally, setting a new standard for vascular therapy.
Korea Herald
7 hours ago
- Korea Herald
Neurophet Participates in BIO USA 2025: To showcase Brain Imaging Analysis Solutions Including 'Neurophet AQUA AD'
SEOUL, South Korea, June 13, 2025 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on the 13th that it will participate in the 2025 BIO International Convention (BIO USA), which will be held in Boston, USA from June 16 to 19 (local time). At this year's BIO USA, Neurophet will introduce its software solution, Neurophet AQUA AD, which enables monitoring of prescription, treatment efficacy, and side effects of treatment for Alzheimer's disease. Neurophet AQUA AD provides precise brain imaging analysis throughout the course of anti-amyloid antibody therapy by quantitatively analyzing MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography) scans. Lately, Alzheimer's disease clinical trials have been rising significantly in the biopharmaceutical industry which led to the importance of quantitative brain imaging biomarker analysis. Alzheimer's disease drugs such as Leqembi (lecanemab) and Kisunla (donanemab) require essential monitoring for potential side effects, which Neurophet AQUA AD can provide and meet demand for global expectations. Neurophet will exhibit at the Korea Pavilion, jointly organized by the Korea Biotechnology Industry Organization and the Korea Trade-Investment Promotion Agency (KOTRA), and showcase Neurophet AQUA AD along with its suite of neuroimaging and brain stimulation solutions. It includes Neurophet AQUA, a neurodegeneration imaging analysis software; Neurophet SCALE PET, a PET image quantification software; Neurophet tES LAB, a treatment planning software for brain stimulation; and Neurophet innk, a transcranial electrical stimulation (tES) device. Neurophet plans to strengthen its imaging CRO (Contract Research Organization) business for clinical trials related to Alzheimer's disease treatment through business meetings at this year's BIO USA. The company will also engage in partnering activities with global big pharma and potential clients. Jake Junkil Been, Co-CEO of Neurophet said that "Neurophet AQUA AD has garnered significant interest from both South Korea and global companies in the field of brain imaging-based biomarker development. Through our participation in BIO USA, we aim to accelerate business development collaborations in the imaging CRO sector and further expand into the companion diagnostics market." BIO USA is the world's largest biotechnology exhibition, serving as a global networking hub where stakeholders across the pharmaceutical and biotech industries come together to explore partnership opportunities. This year's event is expected to host over 1,500 companies and more than 20,000 participants from around the world. About Neurophet Neurophet specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system. Major products include brain MRI analysis software "Neurophet AQUA", PET Image Quantitative Analysis Software "Neurophet SCALE PET", Brain imaging treatment planning software for electric and magnetic brain stimulation "Neurophet tES/TMS LAB", Alzheimer's Disease treatment prescription and monitoring software "Neurophet AQUA AD" for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software "Neurophet AQUA MS". Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.
